SBFM
NASDAQSunshine Biopharma Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$0.91-1.40 (-60.53%)
2026-06-152026-09-17
News · 26 weeks43+57%
2026-03-222026-09-13
Mix2390d
- SEC Filings11(48%)
- Market9(39%)
- Other2(9%)
- Insider1(4%)
Latest news
25 items- SECSEC Form PRE 14C filed by Sunshine Biopharma Inc.PRE 14C - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling StudiesNanomolar potency against PLpro with broad-spectrum SARS-CoV-2 variants activitySignificant dose-dependent suppression of pulmonary viral replication in vivoStrong oral bioavailability and preferential lung enrichment across multiple species Nanomolar potency against PLpro with broad-spectrum SARS-CoV-2 variants activitySignificant dose-dependent suppression of pulmonary viral replication in vivoStrong oral bioavailability and preferential lung enrichment across multiple species FORT LAUDERDALE, FL / ACCESS Newswire / September 16, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medication
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Other Events8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form EFFECT filed by Sunshine Biopharma Inc.EFFECT - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form 424B3 filed by Sunshine Biopharma Inc.424B3 - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSHealth Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular ConditionsFORT LAUDERDALE, FL / ACCESS Newswire / August 31, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its Atenolol tablets of 25mg, 50mg and 100mg for the Canadian market. Atenolol is the generic equivalent of the brand name, Tenormin®.Atenolol belongs to a class of drugs known as beta-blockers. It works by blocking the action of certain natural chemicals in the body, such as epinephrine, on the heart and blood vessels. This effect lowers the heart rate, blood pressure, and strain on the heart.Atenolol is primarily indicated for:Hypertension Manag
- SECSEC Form S-1 filed by Sunshine Biopharma Inc.S-1 - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Leadership Update8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- PRA Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest OpportunityNEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - If watching where cancer treatment is headed, mRNA cancer vaccines are hard to ignore—especially in lung cancer. The basic idea is surprisingly straightforward: instead of giving the immune system a one-size-fits-all treatment, an mRNA vaccine can be designed to teach it what a particular tumor looks like and help it go after those cancer cells. That matters in lung cancer because every tumor can be different, and some eventually learn how to get around existing treatments. Researchers are now looking at whether personalized mRNA vaccines can work alongside today’s immunotherapies to give the immune system a
- NEWSSunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung CancerK1.1 mRNA demonstrated tumor-suppressing activity as a single agent in multiple in vivo hepatocellular carcinoma modelsProgram targets a tumor suppressor frequently mutated in difficult-to-treat lung, pancreatic and liver cancersNext phase will combine K1.1 mRNA with a cancer vaccine in NSCLC with the goal of converting "cold" tumors into "hot" tumors FORT LAUDERDALE, FL / ACCESS Newswire / August 26, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company offering and researching life-saving medicines across multiple therapeutic areas including oncology and antivirals, today provided an update and outlined next plans for its oncology project, the K1.1
- NEWSSunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug MarketGlobal anti-hypertensive drug market projected to reach $37.24 billion by 2034Enalapril is a widely prescribed ACE inhibitor used to treat hypertension, heart failure and left ventricular dysfunctionSunshine Biopharma expects Enalapril tablets in four dosage strengths to begin shipping to Canadian pharmacies by year-end 2026 FORT LAUDERDALE, FL / ACCESS Newswire / August 19, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Enalapril tablets 2.5mg, 5mg, 10mg and 20mg for the Canadian market. Enalapril is the generic equivalent of the
- SECSEC Form 10-Q filed by Sunshine Biopharma Inc.10-Q - Sunshine Biopharma Inc. (0001402328) (Filer)
- INSIDERDirector Natan David was granted 58,300 shares, increasing direct ownership by 583% to 68,300 units (SEC Form 4)4 - Sunshine Biopharma Inc. (0001402328) (Issuer)
- NEWSSunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global MarketSunshine Biopharma's Amoxicillin now shipping to Canadian pharmacies in multiple dosages and strengthsLaunch expands Sunshine Biopharma's growing portfolio of essential prescription medicationsGlobal Amoxicillin market projected to reach approximately $6.4 billion by 2031 FORT LAUDERDALE, FL / ACCESS Newswire / August 7, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the launch of its generic Amoxicillin formulation in the Canadian market. This strategic expansion reinforces Sunshine Biopharma's commitment to providing affordable, high-quality antibiotics to
- NEWSSunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory ApprovalDienogest is first-line therapy for pelvic pain associate with endometriosisThe endometriosis treatment market is projected to reach $5.2 billion by 2034 FORT LAUDERDALE, FL / ACCESS Newswire / August 4, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Dienogest tablets of 2mg for the Canadian market. Dienogest is the generic equivalent of the brand name, Visanne®.Dienogest works through progesterone receptor binding, local anti-inflammatory actions, and mild hormone suppression. It reduces endometriosis pain by shrinking abnormal ti
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Other Events8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSHealth Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and VomitingFORT LAUDERDALE, FL / ACCESS Newswire / July 28, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Ondansetron tablets of 4mg and 8mg for the Canadian market. Ondansetron is the generic equivalent of the brand name, Zofran®.Ondansetron is highly prescribed for nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. Ondansetron is a prescription serotonin 5-HT3 receptor antagonist. It works by blocking the actions of chemicals in the body that trigger nausea and vomiting. By offering both standard film-coated
- SECSEC Form 424B5 filed by Sunshine Biopharma Inc.424B5 - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma and University of Arizona Publish Significant New Research FindingsFORT LAUDERDALE, FL / ACCESS Newswire / July 20, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications today announced the publication of new research results in the Journal of Medicinal Chemistry. The published data demonstrate a novel PLpro inhibitor, MR1-114, with nanomolar potency in at least three variants of the SARS-CoV-2 virus in vitro. MR1-114 was found to be efficacious in a mouse model of SARS-CoV-2 infection by repeated oral administration. This peer-reviewed study marks an important milestone for Sunshine Biopharma in its effort to develop an effective treatment for SARS Coron
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)FORT LAUDERDALE, FL / ACCESS Newswire / June 25, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Anastrozole tablets of 1mg for the Canadian market. Anastrozole is the generic equivalent of the brand name breast cancer drug, Arimidex®.Anastrozole is a highly prescribed non-steroidal aromatase inhibitor. It works by lowering estrogen levels in the body to slow down or reverse the growth of specific breast tumors. Anastrozole is standard care for the adjuvant treatment of postmenopausal women with hormone receptor-positive breast canc
- SECSEC Form DEF 14C filed by Sunshine Biopharma Inc.DEF 14C - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)FORT LAUDERDALE, FL / ACCESS Newswire / June 1, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Rivaroxaban tablets of 2.5mg, 10mg, 15mg and 20mg for the Canadian market. Rivaroxaban is the generic equivalent of the brand name anticoagulant, Xarelto®.Rivaroxaban is a direct oral anticoagulant prescribed to treat and prevent deep vein thrombosis and pulmonary embolism. It is also widely utilized to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.The global market for Rivaroxaban is es
SBFM FAQ
5 questionsWhat does Sunshine Biopharma Inc. do?
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a...Where does SBFM stock trade?
Sunshine Biopharma Inc. (SBFM) is listed on NASDAQ.What sector and industry is SBFM in?
Sunshine Biopharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to SBFM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SBFM side-by-side with any of them on Quantisnow.How can I track SBFM on Quantisnow?
Quantisnow aggregates Sunshine Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SBFM to receive live email and push alerts on every new disclosure.